arsenic trioxide has been researched along with Hemorrhagic Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adès, L; Avvisati, G; Burnett, AK; Chen, SJ; Döhner, H; Estey, EH; Fenaux, P; Iland, H; Kantarjian, H; Lengfelder, E; Lo-Coco, F; Löwenberg, B; Mathews, V; Montesinos, P; Naoe, T; Platzbecker, U; Ravandi, F; Rego, E; Russell, NH; Sanz, MA; Tallman, MS | 1 |
| Cull, EH; Kwaan, HC | 1 |
| Lo-Coco, F; Testa, U | 1 |
3 review(s) available for arsenic trioxide and Hemorrhagic Disorders
| Article | Year |
|---|---|
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Topics: Aged; Arsenic Trioxide; Disease Management; Female; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Practice Guidelines as Topic; Pregnancy; Recurrence; Tretinoin | 2019 |
The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
Topics: Annexin A2; Anticoagulants; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Coagulation Tests; Carboxypeptidase B2; Disseminated Intravascular Coagulation; Fibrinolysis; Forecasting; Granulocyte Precursor Cells; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Risk Factors; S100 Proteins; Thrombomodulin; Thrombophilia; Thromboplastin; Tretinoin; Urokinase-Type Plasminogen Activator | 2014 |
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Disseminated Intravascular Coagulation; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Hemorrhagic Disorders; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocyte Count; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Risk Factors; Tandem Repeat Sequences; Treatment Outcome; Tretinoin; Tumor Protein p73; Tumor Suppressor Proteins | 2016 |